NCT01685008 - Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2013

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2022

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG

MOR00208 (formerly Xmab 5574)

Trial Locations (22)

Morphosys Research Site, Columbus

Morphosys Research Site, Lubbock

MorphoSys Research Site, Norwalk

MorphoSys Research Site, Hackensack

MorphoSys Research Site, Brussels

MorphoSys Research Site, Edegem

MorphoSys Research Site, Berlin

MorphoSys Research Site, Mainz

Morphosys Research Site, Ulm

Morphosys Research Site, Budapest

Morphosys Research Site, Debrecen

MorphoSys Research Site, Bologna

MorphoSys Research Site, Florence

Morphosys, Genova

Morphosys Research Site, Modena

Morphosys Research Site, Novara

MorphoSys Research Site, Chorzów

Morphosys Research Site, Krakow

Morphosys Research Site, Lódz

MorphoSys Research Site, Słupsk

Morphosys Research Site, Madrid

Morphosys Research Site, Seville